SLC5A2 and Abnormal renal physiology: In a meta-analysis study, it was documented that GLP-1 receptor agonist and SGLT-2 inhibitor reduced the risk of CVD mortality (OR = 0.87 and 0.82, respectively), and had potentials in reducing renal dysfunction (32).